Pfizer announced that its next-generation breast cancer drug atirmociclib has succeeded in Phase 2 clinical trials. The experimental treatment is a CDK4 inhibitor being developed as a potential successor to the company's existing breast cancer therapy.
The development comes as the pharmaceutical industry continues efforts to improve cancer treatment options with more targeted therapies. CDK4 inhibitors represent a newer class of cancer drugs that work by blocking specific proteins involved in cell division.